La FDA approuvera-t-elle le bépirovirsen contre l'hépatite B chronique ?

• Ce qui fait monter. Bepirovirsen was granted Priority Review on 28 April 2026 with a PDUFA target date of 26 October 2026, indicating unmet medical need and streamlined review [1].
• Ce qui fait monter. With only eight days remaining before the PDUFA date, there have been no public reports of negative advisory committee votes, clinical holds, or review disruptions [1, 2].
• Ce qui fait descendre. The resolution criteria strictly require approval on or before 26 October 2026; standard FDA 3-month major amendment review extensions or administrative delays resolve as NO [1].
• Ce qui fait descendre. First-in-class antisense oligonucleotides face substantial regulatory scrutiny regarding long-term safety, durability of functional cure, and CMC/manufacturing consistency [1].
• Ce qui ferait le plus bouger ce chiffre. Whether the FDA issues an approval by the 26 October 2026 PDUFA deadline or issues a Complete Response Letter / 3-month review extension for further data analysis.

• Ce qui fait monter. The FDA granted Priority Review, which is reserved for drugs that offer significant improvements in the treatment, diagnosis, or prevention of serious conditions [Starting State, Tier 1].
• Ce qui fait monter. GSK is actively investing $800M in R&D and manufacturing hubs, signaling corporate confidence in their pipeline and production capacity [19, Tier 2].
• Ce qui fait monter. As of 9 days before the PDUFA date, there have been no reports of regulatory delays, manufacturing issues, or negative Advisory Committee outcomes [Starting State, Tier 1].
• Ce qui fait descendre. As a potential first-in-class antisense oligonucleotide, the drug faces the high scrutiny typical of novel therapeutic categories [Starting State, Tier 1].
• Ce qui fait descendre. Any last-minute manufacturing site corrections or data queries could trigger a review extension, which would result in a NO resolution given the October 26 deadline [22, Tier 2].
• Ce qui ferait le plus bouger ce chiffre. The primary uncertainty is whether the FDA's clinical review of the 'functional cure' data meets the high efficacy bar required for a first-in-class approval in chronic hepatitis B.

• Ce qui fait monter. FDA granted Priority Review to bepirovirsen, indicating the agency recognized its potential to offer significant improvements over existing chronic hepatitis B therapies [tier 1]
• Ce qui fait monter. With only 10 days remaining until the 26 October 2026 PDUFA date, no three-month review extension or major regulatory hold has been announced [tier 1]
• Ce qui fait descendre. Resolution strictly requires approval on or before 26 October 2026; any last-minute review postponement or Complete Response Letter (CRL) immediately resolves the question as NO [tier 1]
• Ce qui fait descendre. As a first-in-class antisense oligonucleotide targeting functional cure, clinical evaluation faces stringent regulatory scrutiny regarding sustained off-treatment efficacy and safety (e.g., ALT flare monitoring) [tier 1]
• Ce qui ferait le plus bouger ce chiffre. Whether the FDA issues an on-schedule approval or encounters a last-minute manufacturing/clinical review hurdle resulting in a CRL or extension.

• Ce qui fait monter. Priority Review status indicates the FDA considers the drug a significant improvement over existing treatments for chronic hepatitis B [Starting State]
• Ce qui fait monter. The PDUFA date is only 11 days away with no public reports of negative Advisory Committee outcomes or clinical holds [Starting State]
• Ce qui fait monter. GSK is strengthening its US manufacturing and R&D infrastructure, which supports the operational requirements for a new product launch [17]
• Ce qui fait descendre. Manufacturing site corrections can lead to unexpected review extensions or Complete Response Letters, even for major pharmaceutical companies [20]
• Ce qui fait descendre. As a first-in-class antisense oligonucleotide, the drug faces high regulatory scrutiny regarding its novel mechanism and long-term safety profile [Starting State]
• Ce qui ferait le plus bouger ce chiffre. The potential for last-minute manufacturing inspection failures or the FDA requesting additional safety data before the PDUFA deadline.

• Ce qui fait monter. Priority Review was granted by the FDA with a target PDUFA date of 26 October 2026 for a potential first-in-class functional cure [1].
• Ce qui fait monter. There are no public reports of negative Advisory Committee votes, safety holds, or manufacturing concerns regarding bepirovirsen as of 14 October 2026 [1, 2].
• Ce qui fait descendre. The resolution criteria require approval on or before 26 October 2026; any review extension (such as the 3-month extension for manufacturing reviews common across novel biologics) results in a NO [2].
• Ce qui fait descendre. First-in-class antisense oligonucleotides targeting functional cure in chronic hepatitis B face rigorous regulatory review of durability, safety, and biomarker validation [1].
• Ce qui ferait le plus bouger ce chiffre. Whether the FDA issues a standard three-month review extension or complete response letter regarding chemistry, manufacturing, and controls (CMC) or clinical endpoints prior to the October 26 deadline.

• Ce qui fait monter. The FDA granted Priority Review, which is typically reserved for drugs that offer significant improvements in treatment [1]
• Ce qui fait monter. Bepirovirsen is described as a potential first-in-class functional cure for chronic hepatitis B, addressing a high unmet medical need [1]
• Ce qui fait monter. GSK is making substantial investments in its R&D and manufacturing infrastructure, signaling confidence in its pipeline [2]
• Ce qui fait descendre. First-in-class antisense oligonucleotides face high regulatory scrutiny regarding long-term safety and efficacy [1]
• Ce qui fait descendre. Manufacturing site corrections can lead to review extensions or rejections, as seen recently with other major pharma applications [2]
• Ce qui ferait le plus bouger ce chiffre. The primary uncertainty is whether any undisclosed manufacturing issues or late-cycle safety concerns will prompt the FDA to issue a Complete Response Letter instead of an approval.

• Ce qui fait monter. Bepirovirsen was granted Priority Review by the FDA, reflecting significant potential therapeutic advance in chronic hepatitis B [tier 1]
• Ce qui fait monter. With only two weeks remaining until the 26 October 2026 PDUFA date, no negative Advisory Committee outcomes, clinical holds, or preliminary CRL signals have emerged in official or trade channels [tier 1, tier 2]
• Ce qui fait descendre. Any last-minute 3-month PDUFA extension due to manufacturing or data review amendments would push the decision past 26 October 2026, triggering a NO resolution under the criterion [tier 1]
• Ce qui fait descendre. Novel mechanism oligonucleotides carry non-negligible risks of Complete Response Letters regarding safety, liver toxicity profile, or CMC specifications on first cycle review [tier 1]
• Ce qui ferait le plus bouger ce chiffre. Whether the FDA issues an approval by the target date or extends review/issues a CRL regarding manufacturing or long-term safety data.

• Ce qui fait monter. The FDA granted Priority Review, indicating the drug offers a significant improvement in treatment [1].
• Ce qui fait monter. Bepirovirsen is described as delivering clinically meaningful functional cure rates, a high-value endpoint in chronic hepatitis B [1].
• Ce qui fait monter. With only 16 days remaining until the PDUFA date, there have been no reports of manufacturing issues or clinical holds specific to this application [1, 2].
• Ce qui fait monter. GSK has secured recent regulatory wins in this therapeutic area, suggesting positive momentum [2].
• Ce qui fait descendre. As a first-in-class antisense oligonucleotide, it faces higher scrutiny regarding long-term safety and the novel mechanism [1].
• Ce qui fait descendre. Manufacturing site corrections are a common cause for last-minute FDA review extensions or rejections in the current regulatory environment [2].
• Ce qui ferait le plus bouger ce chiffre. The primary uncertainty is whether the FDA's assessment of the 'functional cure' data meets the threshold for a first-in-class approval without requiring additional long-term safety data.

Raisons non conservées pour cette révision (l'historique détaillé n'est gardé que depuis peu).

Raisons non conservées pour cette révision (l'historique détaillé n'est gardé que depuis peu).